CoChat

Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy

Open access
Martier, Raygene, Liefhebber, Jolanda M., García-Osta, Ana, Miniarikova, Jana, Cuadrado-Tejedor, Mar, Espelosin, Maria, Ursua, Susana, Petry, Harald, van Deventer, Sander J., Evers, Melvin M., Konstantinova, Pavlina · 2019 · Molecular Therapy - Nucleic Acids
Cited by 89

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

A hexanucleotide GGGGCC expansion in intron 1 of chromosome 9 open reading frame 72 (C9orf72) gene is the most frequent cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The corresponding repeat-containing sense and antisense transcripts cause a gain of toxicity through the accumulation of RNA foci in the nucleus and deposition of dipeptide-repeat (DPR) proteins in the cytoplasm of the affected cells. We have previously reported on the potential of engineered artificial anti-C9orf72-targeting miRNAs (miC) targeting C9orf72 to reduce the gain of toxicity caused by the repeat-containing transcripts. In the current study, we tested the silencing efficacy of adeno-associated virus (AAV)5-miC in human-derived induced pluripotent stem cell (iPSC) neurons and in an ALS mouse model. We demonstrated that AAV5-miC transduces different types of neuronal cells and can reduce the accumulation of repeat-containing C9orf72 transcripts. Additionally, we demonstrated silencing of C9orf72 in both the nucleus and cytoplasm, which has an added value for the treatment of ALS and/or FTD patients. A proof of concept in an ALS mouse model demonstrated the significant reduction in repeat-containing C9orf72 transcripts and RNA foci after treatment. Taken together, these findings support the feasibility of a gene therapy for ALS and FTD based on the reduction in toxicity caused by the repeat-containing C9orf72 transcripts.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.omtn.2019.02.001

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 44

  1. Ferrari, 2011, FTD and ALS: a tale of two diseases, Curr. Alzheimer Res., 8, 273, 10.2174/156720511795563700 · DOI · Paper page
  2. Liscic, 2008, ALS and FTLD: two faces of TDP-43 proteinopathy, Eur. J. Neurol., 15, 772, 10.1111/j.1468-1331.2008.02195.x · DOI · Paper page
  3. Heutink, 2014, C9orf72; abnormal RNA expression is the key, Exp. Neurol., 262, 102, 10.1016/j.expneurol.2014.05.020 · DOI
  4. Gendron, 2014, Mechanisms of toxicity in C9FTLD/ALS, Acta Neuropathol., 127, 359, 10.1007/s00401-013-1237-z · DOI · Paper page
  5. Liu, 2017, c9orf72 Disease-Related Foci Are Each Composed of One Mutant Expanded Repeat RNA, Cell Chem. Biol., 24, 141, 10.1016/j.chembiol.2016.12.018 · DOI
  6. Cooper-Knock, 2014, Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions, Brain, 137, 2040, 10.1093/brain/awu120 · DOI · Paper page
  7. Zu, 2013, RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia, Proc. Natl. Acad. Sci. USA, 110, E4968, 10.1073/pnas.1315438110 · DOI · Paper page
  8. Wojciechowska, 2011, Cellular toxicity of expanded RNA repeats: focus on RNA foci, Hum. Mol. Genet., 20, 3811, 10.1093/hmg/ddr299 · DOI · Paper page
  9. Lagier-Tourenne, 2013, Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration, Proc. Natl. Acad. Sci. USA, 110, E4530, 10.1073/pnas.1318835110 · DOI · Paper page
  10. Freibaum, 2017, The Role of Dipeptide Repeats in C9ORF72-Related ALS-FTD, Front. Mol. Neurosci., 10, 35, 10.3389/fnmol.2017.00035 · DOI · Paper page
  11. Ash, 2013, Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS, Neuron, 77, 639, 10.1016/j.neuron.2013.02.004 · DOI · Paper page
  12. Scaber, 2016, What is the role of TDP-43 in C9orf72-related amyotrophic lateral sclerosis and frontemporal dementia?, Brain, 139, 3057, 10.1093/brain/aww264 · DOI
  13. Gijselinck, 2012, A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study, Lancet Neurol., 11, 54, 10.1016/S1474-4422(11)70261-7 · DOI · Paper page
  14. Brettschneider, 2012, Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion, Acta Neuropathol., 123, 825, 10.1007/s00401-012-0970-z · DOI · Paper page
  15. Liu, 2016, C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD, Neuron, 90, 521, 10.1016/j.neuron.2016.04.005 · DOI · Paper page
  16. Hu, 2017, Recognition of c9orf72 Mutant RNA by Single-Stranded Silencing RNAs, Nucleic Acid Ther., 27, 87, 10.1089/nat.2016.0655 · DOI
  17. Hu, 2015, Engineering Duplex RNAs for Challenging Targets: Recognition of GGGGCC/CCCCGG Repeats at the ALS/FTD C9orf72 Locus, Chem. Biol., 22, 1505, 10.1016/j.chembiol.2015.09.016 · DOI
  18. Graves, 2012, Biogenesis of mammalian microRNAs: a global view, Genomics Proteomics Bioinformatics, 10, 239, 10.1016/j.gpb.2012.06.004 · DOI
  19. Martier, 2019, Artificial microRNAs targeting C9ORF72 have the potential to reduce accumulation of the intra-nuclear transcripts in ALS and FTD patients, Mol. Ther. Nucleic Acids, 10.1016/j.omtn.2019.01.010 · DOI
  20. Lee, 2017, Modeling ALS and FTD with iPSC-derived neurons, Brain Res., 1656, 88, 10.1016/j.brainres.2015.10.003 · DOI · Paper page
  21. Di Giorgio, 2008, Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation, Cell Stem Cell, 3, 637, 10.1016/j.stem.2008.09.017 · DOI · Paper page
  22. Selvaraj, 2017, Modeling the C9ORF72 repeat expansion mutation using human induced pluripotent stem cells, Brain Pathol., 27, 518, 10.1111/bpa.12520 · DOI
  23. Peters, 2015, Human C9ORF72 Hexanucleotide Expansion Reproduces RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC Transgenic Mice, Neuron, 88, 902, 10.1016/j.neuron.2015.11.018 · DOI · Paper page
  24. Lee, 2004, MicroRNA genes are transcribed by RNA polymerase II, EMBO J., 23, 4051, 10.1038/sj.emboj.7600385 · DOI · Paper page
  25. Kim, 2006, Genomics of microRNA, Trends Genet., 22, 165, 10.1016/j.tig.2006.01.003 · DOI · Paper page
  26. Winter, 2009, Many roads to maturity: microRNA biogenesis pathways and their regulation, Nat. Cell Biol., 11, 228, 10.1038/ncb0309-228 · DOI · Paper page
  27. Tyzack, 2016, Human Stem Cell-Derived Astrocytes: Specification and Relevance for Neurological Disorders, Curr. Stem Cell Rep., 2, 236, 10.1007/s40778-016-0049-1 · DOI · Paper page
  28. Xu, 2013, Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration, Proc. Natl. Acad. Sci. USA, 110, 7778, 10.1073/pnas.1219643110 · DOI · Paper page
  29. van Blitterswijk, 2015, Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72, Acta Neuropathol., 130, 863, 10.1007/s00401-015-1480-6 · DOI · Paper page
  30. Rizzu, 2016, C9orf72 is differentially expressed in the central nervous system and myeloid cells and consistently reduced in C9orf72, MAPT and GRN mutation carriers, Acta Neuropathol. Commun., 4, 37, 10.1186/s40478-016-0306-7 · DOI · Paper page
  31. Dodge, 2010, AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice, Mol. Ther., 18, 2075, 10.1038/mt.2010.206 · DOI · Paper page
  32. Koppers, 2015, C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits, Ann. Neurol., 78, 426, 10.1002/ana.24453 · DOI · Paper page
  33. O’Rourke, 2016, C9orf72 is required for proper macrophage and microglial function in mice, Science, 351, 1324, 10.1126/science.aaf1064 · DOI · Paper page
  34. Niblock, 2016, Retention of hexanucleotide repeat-containing intron in C9orf72 mRNA: implications for the pathogenesis of ALS/FTD, Acta Neuropathol. Commun., 4, 18, 10.1186/s40478-016-0289-4 · DOI
  35. Fratta, 2012, C9orf72 hexanucleotide repeat associated with amyotrophic lateral sclerosis and frontotemporal dementia forms RNA G-quadruplexes, Sci. Rep., 2, 1016, 10.1038/srep01016 · DOI · Paper page
  36. Reddy, 2013, The disease-associated r(GGGGCC)n repeat from the C9orf72 gene forms tract length-dependent uni- and multimolecular RNA G-quadruplex structures, J. Biol. Chem., 288, 9860, 10.1074/jbc.C113.452532 · DOI · Paper page
  37. Su, 2014, Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS, Neuron, 83, 1043, 10.1016/j.neuron.2014.07.041 · DOI · Paper page
  38. Nordin, 2017, Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study, Amyotroph. Lateral Scler. Frontotemporal Degener., 18, 256, 10.1080/21678421.2016.1262423 · DOI
  39. Prudencio, 2015, Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS, Nat. Neurosci., 18, 1175, 10.1038/nn.4065 · DOI · Paper page
  40. Han, 2004, The Drosha-DGCR8 complex in primary microRNA processing, Genes Dev., 18, 3016, 10.1101/gad.1262504 · DOI · Paper page
  41. Liu, 2018, Nuclear functions of mammalian MicroRNAs in gene regulation, immunity and cancer, Mol. Cancer, 17, 64, 10.1186/s12943-018-0765-5 · DOI · Paper page
  42. Schraivogel, 2014, Import routes and nuclear functions of Argonaute and other small RNA-silencing proteins, Trends Biochem. Sci., 39, 420, 10.1016/j.tibs.2014.07.004 · DOI
  43. Miniarikova, 2016, Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington’s Disease, Mol. Ther. Nucleic Acids, 5, e297, 10.1038/mtna.2016.7 · DOI · Paper page
  44. Pascual-Lucas, 2014, Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice, EMBO Mol. Med., 6, 1246, 10.15252/emmm.201404228 · DOI · Paper page

Cited by

See all 89

Metadata

Authors
Martier, R., Liefhebber, J. M., García-Osta, A., Miniarikova, J., Cuadrado-Tejedor, M., Espelosin, M., Ursua, S., Petry, H., van Deventer, S. J., Evers, M. M., & Konstantinova, P.
Venue
Molecular Therapy - Nucleic Acids
Publisher
Elsevier BV
Published
2019-06
Volume
16
Pages
26-37
ISSN
2162-2531 (ISSN-L)
OpenAlex
W2914096858
Cited by
89
References
19
FWCI
8.00
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy. https://app.cochat.ai/papers/10.1016/j.omtn.2019.02.001
The paper
Martier, R., Liefhebber, J. M., García-Osta, A., Miniarikova, J., Cuadrado-Tejedor, M., Espelosin, M., Ursua, S., Petry, H., van Deventer, S. J., Evers, M. M., & Konstantinova, P. (2019). Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy. Molecular Therapy - Nucleic Acids. https://doi.org/10.1016/j.omtn.2019.02.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.